Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
•ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) - <5
•Amivantamab - NIL
•Atezolizumab Monotherapy - 6
•Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel - <5
•Dabrafenib + Trametinib - NIL
•Docetaxel monotherapy or in combination with Carboplatin/Cisplatin - <5
•Durvalumab - <5
•Gemcitabine - <5 (combination with carboplatin)
•Nitedanib + Docetaxel - <5
•Nivolumab - <5 (combination with carboplatin & paclitaxel)
•Osimertinib - 13
•Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) - <5
•Paclitaxel - 24 (in combination with other agents)
•Pembrolizumab Monotherapy - 20
•Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 13
•Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) - 13
•Pemetrexed + Platinum (Carboplatin/Cisplatin) - 5
•RET Inhibitors (Pralsetinib, Selpercatinib) - <5
•Sotorasib - <5
•Tepotinib - NIL
•Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - <5
•Other active systemic anti-cancer therapy - <5
•Palliative care only - 7
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
•Atezolizumab monotherapy - 6
•Durvalumab - <5
•Gemcitabine - <5 (in combination with carboplatin)
•Nivolumab - 1 (in combination with carboplatin and paclitaxel)
•Osimertinib - 16
•Pembrolizumab (Keytruda) Mono - 20
•Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 14
•Paclitaxel - NIL in monotherapy, 25 in combination
•Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - <5
•Other active systemic anti-cancer therapy (SACT) - 36
•Palliative care only - <5
